Cargando…

Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum

BACKGROUND: Cysteamine has recently been shown to have in vitro properties potentially therapeutically beneficial in cystic fibrosis (CF). In this study we investigated the antimicrobial and mucolytic activity of cysteamine against the complex biologic matrix of CF sputum. METHODS: Sputum samples we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devereux, Graham, Fraser-Pitt, Douglas, Robertson, Jennifer, Devlin, Edward, Mercer, Derry, O'Neil, Deborah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634621/ https://www.ncbi.nlm.nih.gov/pubmed/26629546 http://dx.doi.org/10.1016/j.ebiom.2015.08.018

Ejemplares similares

Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis
por: Charrier, Cedric, et al.
Publicado: (2014)

Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex
por: Fraser-Pitt, Douglas, et al.
Publicado: (2016)

An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis
por: Devereux, Graham, et al.
Publicado: (2016)

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial
por: Devereux, Graham, et al.
Publicado: (2020)

Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
por: Volpi, Sonia, et al.
Publicado: (2022)

Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa
por: Fraser-Pitt, Douglas J., et al.
Publicado: (2021)

Cystic fibrosis – a multiorgan protein misfolding disease
por: Fraser-Pitt, Douglas, et al.
Publicado: (2015)

Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection
por: Fraser-Pitt, Douglas J., et al.
Publicado: (2018)

Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?
por: Scaglione, Francesco, et al.
Publicado: (2019)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

A Breathe in Cystic Fibrosis Therapy: A New Therapeutic Endeavor for Cysteamine
por: De Stefano, Daniela, et al.
Publicado: (2015)

Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages
por: Shrestha, Chandra L., et al.
Publicado: (2017)

Azithromycin and the microbiota of cystic fibrosis sputum
por: Acosta, Nicole, et al.
Publicado: (2021)

A reappraisal of the mucoactive activity and clinical efficacy of bromhexine
por: Zanasi, Alessandro, et al.
Publicado: (2017)

Neutrophil count in sputum is associated with increased sputum glucose and sputum L-lactate in cystic fibrosis
por: Nielsen, Bibi Uhre, et al.
Publicado: (2020)

Rational use of mucoactive medications to treat pediatric airway disease
por: Linssen, R.S.N., et al.
Publicado: (2020)

Analysis of Pseudomonas aeruginosa transcription in an ex vivo cystic fibrosis sputum model identifies metal restriction as a gene expression stimulus
por: Neff, Samuel L., et al.
Publicado: (2023)

Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients
por: Al-momani, H., et al.
Publicado: (2016)

The Inhibition of Superoxide Production by the Soluble Phase of Cystic Fibrosis Sputum
por: Dosanjh, Amrita
Publicado: (2008)

Sputum Biomarkers and the Prediction of Clinical Outcomes in Patients with Cystic Fibrosis
por: Liou, Theodore G., et al.
Publicado: (2012)

Isolation and characterization of microparticles in sputum from cystic fibrosis patients
por: Porro, Chiara, et al.
Publicado: (2010)

Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis
por: Horsley, Alex, et al.
Publicado: (2014)

Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome
por: Quinn, Robert A, et al.
Publicado: (2016)

Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
por: Breen, Paul, et al.
Publicado: (2022)

Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians
por: Yan, Xixin, et al.
Publicado: (2017)

Profiling of Bacterial and Fungal Microbial Communities in Cystic Fibrosis Sputum Using RNA
por: Grahl, Nora, et al.
Publicado: (2018)

Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
por: Mercer, Derry K., et al.
Publicado: (2020)

Mucoactive agent use in adult UK Critical Care Units: a survey of health care professionals’ perception, pharmacists’ description of practice, and point prevalence of mucoactive use in invasively mechanically ventilated patients
por: Borthwick, Mark, et al.
Publicado: (2020)

Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum
por: Serisier, David J, et al.
Publicado: (2009)

Contribution by Polymorphonucleate Granulocytes to Elevated Gamma-Glutamyltransferase in Cystic Fibrosis Sputum
por: Corti, Alessandro, et al.
Publicado: (2012)

Antibacterial Effects of Bicarbonate in Media Modified to Mimic Cystic Fibrosis Sputum
por: Jaikumpun, Pongsiri, et al.
Publicado: (2020)

An Innovative Protocol for Metaproteomic Analyses of Microbial Pathogens in Cystic Fibrosis Sputum
por: Graf, Alexander C., et al.
Publicado: (2021)

Apparent Yield Stress of Sputum as a Relevant Biomarker in Cystic Fibrosis
por: Ghanem, Rosy, et al.
Publicado: (2021)

Cystic Fibrosis Sputum Impairs the Ability of Neutrophils to Kill Staphylococcus aureus
por: Fantone, Kayla, et al.
Publicado: (2021)

Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules
por: Schneider-Futschik, Elena K., et al.
Publicado: (2018)

Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation
por: Ferrari, Eleonora, et al.
Publicado: (2017)

Catabolism of Nucleic Acids by a Cystic Fibrosis Pseudomonas aeruginosa Isolate: An Adaptive Pathway to Cystic Fibrosis Sputum Environment
por: Kumar, Sheemal Shanista, et al.
Publicado: (2019)

NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile
por: Mercer, Derry K, et al.
Publicado: (2020)

Activity and Interactions of Liposomal Antibiotics in Presence of Polyanions and Sputum of Patients with Cystic Fibrosis
por: Alipour, Misagh, et al.
Publicado: (2009)

Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach
por: Abrami, Michela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5mg2bh1cf1nlseijcd0rrg22c4